Eisai Posts Anti-seizure Drug Study Results

The study involved 389 people who received either 8mg or 12mg of perampanel or placebo once-daily for 19 weeks in addition to regular treatment.

Japan's pharmaceutical company Eisai has reported the results of its Phase III pivotal study into the investigational compound perampanel as a treatment of partial-onset seizures.

Perampanel, discovered and developed by Eisai, is a highly selective non-competitive AMPA-type glutamate receptor antagonist.

The study involved 389 people who received either 8mg or 12mg of perampanel or placebo once-daily for 19 weeks in addition to regular treatment.

The primary and secondary endpoints were standard median per cent seizure reduction, 50% responder rate, percentage reduction of complex partial plus secondarily generalised seizures and evaluation for dose response.